Revel RX review

Revel offers a documented clinician-mediated compounded GLP-1 pathway with named clinical and pharmacy relationships. Its pricing, subscription terminology and cold-shipping statements leave enough uncertainty that a written treatment quote is essential.

Revel RX describes a telehealth and pharmacy-fulfillment platform rather than a medical practice. Public notices identify Revel Rx LLC, while the about page identifies Brian Conway as founder and CEO. The founder’s personal account is not independent evidence of treatment outcomes.

The platform names MD Integrations as its provider network and Manifest Pharmacy and Red Rock Compounding Pharmacy as possible dispensing partners, depending on therapy. Those disclosures help distinguish administration, prescribing and fulfillment, but do not identify the practice, clinician or pharmacy assigned to an individual order. Published license or certification claims are not independent verification.

The central offer is clinician-reviewed compounded semaglutide or tirzepatide. A pharmacy or network name does not establish a particular prescription’s composition, quality, availability or suitability.

Revel describes an assessment followed by licensed-provider review, a prescription when appropriate, pharmacy fulfillment and check-ins. Adults must be at least eighteen, and access is limited to the United States with restrictions by therapy, medication and state. Selected clinician listings are not a complete state-service roster. Confirm your specific product and location before paying.

Delivery descriptions conflict in a way that matters for planning. The homepage promotes two-day delivery in one place and free overnight cold shipping in another. The return policy instead says refrigerated products are not currently shipped. Neither description resolves your medication’s packaging, carrier service or delivery timing. Ask for its storage and shipment requirements rather than relying on the fastest headline.

The terms allow patients to request another pharmacy before ordering. That choice does not establish that the advertised bundled cost or delivery offer will apply at that pharmacy. Clarify the price and which party handles shipment problems before changing fulfillment arrangements.

Website privacy terms cover purchase, medication-interest, location and device information, analytics and marketing disclosures. The HIPAA notice uses pharmacy-oriented language; it does not clearly identify the separate treating practice’s medical-record notice. Request that practice’s notice as well. The linked safety information page supplies privacy material rather than drug-specific safety guidance, so obtain the relevant medication information directly from the clinician and pharmacy.

The homepage advertises compounded semaglutide at $89 per month and compounded tirzepatide at $155 per month, with all doses at one price, no membership fee, consultation and delivery. Its FAQ also says price depends on medication and program length and that consultation and medication can be billed separately. These qualifications prevent treating either headline as a settled month-to-month total for every patient.

No clear minimum program length, multi-month total, required prepayment, introductory duration or exact dispensed quantity accompanies those claims. Ask for the full initial charge, the period it covers and the cost of later orders. A monthly advertising unit does not establish when the complete bill is due.

Payment and refill FAQs describe no automatic billing: patients log in, request a refill, complete a health check-in, review the order and authorize payment. The separate returns policy nevertheless uses subscription terminology. The stated refill process is useful, but initial consultation timing and the applicability of any recurring authorization remain unclear. Confirm the arrangement for the program actually selected.

Revel describes self-pay care and does not accept insurance. Its terms prohibit submitting the telemedicine claim to government or private payors. HSA/FSA eligibility is left to the plan administrator and should not be treated as an assured reimbursement benefit.

The FAQ says cancellation affects future orders and excludes refunds for shipped medication or completed clinical services. It allows specified exceptions for duplicate or post-cancellation charges, carrier-confirmed loss and material fulfillment errors, with reporting within five business days and approved-refund processing estimated at five to ten business days. It also limits disputes older than sixty days without prior contact.

The returns policy allows changes before shipment, makes prescription sales final once charged and handed to the carrier, and describes reshipment for lost orders. That lost-order remedy differs from the FAQ’s refund language. A separate thirty-day return rule concerns unopened over-the-counter items, not prescription medication. Obtain the controlling remedy and reporting deadline for your order; neither policy establishes a general medication satisfaction guarantee.

Revel explicitly offers compounded semaglutide and compounded tirzepatide. Exact route, concentration, additives and dispensed volume are not established by the public offer. Illustrative vial images do not settle those details or identify a branded product.

Compounded medications are not FDA approved. Advertised pharmacy relationships, flat-dose pricing and safety claims do not establish equivalence to an approved medicine or suitability for an individual patient. Confirm the exact prescription and instructions with the treating professional and dispensing pharmacy.